WESTBURY, N.Y., Feb. 26, 2013 /PRNewswire/ -- In continuing to spread awareness of the benefits of alternative treatments for heart disease, Vasomedical, Inc. (“Vasomedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® Therapy systems - the gold standard of ECP therapy, and ECG Holter and Ambulatory Blood Pressure monitoring products, will attend and exhibit at the American College of Cardiology‘s Annual Scientific Session from March 9-11, 2013 in San Francisco, California.
The American College of Cardiology’s (ACC) Annual Scientific Session is a yearly meeting in which members of the ACC and medical professionals, both domestic and international, come together to share and discuss the latest developments in cardiovascular health and treatment. Last year, this event attracted more than 13,000 healthcare professionals from across the globe, with more than 4,880 attendees visiting from outside the United States. The event aims to promote the innovative developments and successful practices that impact the delivery of quality care and the prevention of cardiovascular diseases.
Vasomedical will be located at booth S1649 in the South Hall of the Moscone Convention Center. The Company will be conducting demonstrations of its Lumenair EECP therapy system, as well as displaying its line of BIOX ECG Holter and Ambulatory Blood Pressure monitoring products along with other low cost patient management products.
“The world of cardiovascular care is constantly evolving, and at Vasomedical, we aim for our technology to be at the forefront of the non-invasive alternative treatment category. We understand that the ACC continually reevaluates its guidelines and recommendations for the use of EECP Therapy, and as such, we look forward to sharing our progress and engaging in discussion with the medical community at the Annual Scientific Session,” said Dr. Jun Ma, president and chief executive officer of Vasomedical, Inc.
“The ACC and Vasomedical share the same underlying goal, which is to advance the education and development of cardiovascular care so patients are aware of all of their options and receive optimal treatment,” Dr. Ma continued. “By showcasing the EECP technology at this event, we hope to raise awareness about the safety and successes of this therapy. As EECP Therapy has been demonstrated to enhance the lives of patients and also reduce future hospitalizations, it is a great option for those who are suffering from various heart conditions.”
For more information about Vasomedical, visit the Company’s website at www.vasomedical.com.
About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company’s main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company’s China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company’s website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
212-896-1216 / 212-896-1220
lgoldberg@kcsa.com / swolf@kcsa.com
SOURCE Vasomedical, Inc.
